Clinical predictor of survival following docetaxel‑based chemotherapy

Lee,Hsiang‑Ying; Wu,Wen‑Jeng; Huang,Chun‑Hsiung; Chou,Yii‑Her; Huang,Chun‑Nung; Lee,Yung‑Chin; Yang,Kai‑Fu; Lee,Mei‑Hui; Huang,Shu‑Pin

doi:10.3892/ol.2014.2349

Clinical predictor of survival following docetaxel‑based chemotherapy

Authors:
- Hsiang‑Ying Lee
- Wen‑Jeng Wu
- Chun‑Hsiung Huang
- Yii‑Her Chou
- Chun‑Nung Huang
- Yung‑Chin Lee
- Kai‑Fu Yang
- Mei‑Hui Lee
- Shu‑Pin Huang
View Affiliations

Affiliations: Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan, R.O.C.
Published online on: July 14, 2014 https://doi.org/10.3892/ol.2014.2349
Pages: 1788-1792

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate cancer (PCa) is the most common type of cancer in males in the USA and the incidence is increasing. For castration‑resistant PCa (CRPC), previous studies have identified docetaxel‑based chemotherapy as the first-line therapy. In the present study, the efficacy of docetaxel‑based chemotherapy was investigated in a population of patients with CRPC. This study included 26 individuals (mean age, 73 years) with CRPC who were patients between July 2007 and October 2012 at the Kaohsiung Medical University Hospital (Kaohsiung, Taiwan). The regimen consisted of intravenous docetaxel (70 mg/m2) once every four weeks plus oral prednisolone (5 mg) twice daily for five days. Prostate‑specific antigen (PSA) response (defined as a PSA decrease of >50% over four weeks), time to PSA progression, PCa‑specific survival and overall survival (OS) were evaluated. For these 26 patients, the mean PSA level prior to chemotherapy treatment was 335.58 ng/ml. During follow‑up, the average number of cycles of chemotherapy was approximately seven and 15 patients (58%) achieved a PSA response. PSA response was found to significantly correlate with OS and PCa‑specific survival (P=0.014 and P=0.028, respectively). The mean value of the PSA nadir level was 89.97 ng/ml and time to PSA nadir was five months. The most common adverse event was leucopenia, which affected 88% of the patients. The results indicated that the length of time to PSA nadir and the occurrence of leucopenia may impact the PSA response. The docetaxel‑based chemotherapy was a feasible and effective treatment regimen in patients with CRPC. However, the occurrence of adverse events, particularly the high incidence of leucopenia, may be cause for concern.

View Figures

View References

1	Matsuda T, Marugame T, Kamo K, et al: Cancer incidence and incidence rates in Japan in 2005: based on data from 12 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 41:139–147. 2011.
2	Chen CH, Yao HH, Huang SW, et al: Using age-referenced prostate-specific antigen percentile to predict survival outcomes in screened Taiwanese men. Int J Cancer. 132:1927–1932. 2013.
3	Tannock IF, de Wit R, Berry WR, et al; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004.
4	Kuramoto T, Inagaki T, Fujii R, et al: Docetaxel in combination with estramustine and prednisolone for castration-resistant prostate cancer. Int J Clin Oncol. 18:890–897. 2013.
5	Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 351:1513–1520. 2004.
6	Mottet N, Bellmunt J, Bolla M, et al: EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 59:572–583. 2011.
7	Miura N, Numata K, Kusuhara Y, et al: Docetaxel-prednisolone combination therapy for Japanese patients with hormone-refractory prostate cancer: a single institution experience. Jpn J Clin Oncol. 40:1092–1098. 2010.
8	National Cancer Institute. National Cancer Institute common terminology criteria for adverse events version 4.0. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed April 20, 2013
9	Wilson C, Scullin P, Worthington J, et al: Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer. Br J Cancer. 99:2054–2064. 2008.
10	Miyake H, Sakai I, Terakawa T, Harada K and Fujisawa M: Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer. Urol Oncol. 31:733–738. 2013.
11	Naito S, Tsukamoto T, Koga H, et al: Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan. Jpn J Clin Oncol. 38:365–372. 2008.
12	Lee JL, Kim JE, Ahn JH, et al: Efficacy and safety of docetaxel plus prednisolone chemotherapy for metastatic hormone-refractory prostate adenocarcinoma: single institutional study in Korea. Cancer Res Treat. 42:12–17. 2010.
13	Nelius T, Klatte T, de Riese W and Filleur S: Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy. Int Urol Nephrol. 40:97–104. 2008.
14	Thuret R, Massard C, Gross-Goupil M, et al: The postchemotherapy PSA surge syndrome. Ann Oncol. 19:1308–1311. 2008.
15	Olbert PJ, Hegele A, Kraeuter P, et al: Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel. Anticancer Drugs. 17:993–996. 2006.
16	Ide H, Kikuchi E, Kono H, et al: Docetaxel in combination with prednisolone for hormone refractory prostate cancer. Jpn J Clin Oncol. 40:79–84. 2010.
17	Pond GR, Armstrong AJ, Wood BA, et al: Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Eur Urol. 61:363–369. 2012.
18	Masago T, Watanabe T, Nemoto R and Motoda K: Interstitial pneumonitis induced by bicalutamide given for prostate cancer. Int J Clin Oncol. 16:763–765. 2011.
19	Matsumoto A, Inoue A, Yokoi S, et al: Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer. Int J Urol. 16:687–691. 2009.
20	Qi WX, Shen Z and Yao Y: Docetaxel-based therapy with or without estramustine as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials. J Cancer Res Clin Oncol. 137:1785–1790. 2011.
21	Huang SP, Bao BY, Wu MT, et al: Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy. Prostate. 71:1189–1197. 2011.
22	Qu YY, Dai B, Kong YY, Ye DW, Yao XD, Zhang SL, et al: Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Asian J Androl. 15:110–115. 2013.